EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access

Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study

Khalid El Bairi iD, Salma Najem iD, Arman Reza Chowdhury iD, Abeid Omar iD, Omar Abdihamid iD, Laure-Anne Teuwen iD, Nada Benhima iD, Ainhoa Madariaga iD, Safa Elkefi, Fernando Cristobal Diaz iD, Sadaqat Hussain, Kristina Jenei iD und 7 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.24.00167 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Khalid El Bairi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, University Mohammed VI Polytechnic, Ben Guerir, Morocco. Hauptthemen laut MEDLINE: Conflict of Interest, Disclosure, Medical Oncology. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Conflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low- and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI. MATERIALS AND METHODS We designed an online 27-question–based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings. RESULTS ONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI. CONCLUSION These findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conflict of InterestDisclosureMedical OncologyHumansCross-Sectional StudiesFemaleMaleAdultMiddle AgedSurveys and QuestionnairesAgedAged, 80 and overOncologistsPilot ProjectsDeveloping Countries

Autor:innen und Institutionen

  • Faculty of Medical Sciences, University Mohammed VI Polytechnic, Ben Guerir, Morocco.
  • Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
  • Evercare Cancer Centre, Evercare Hospital, Dhaka, Bangladesh.
  • Department of Oncology and Nuclear Medicine, Research and Referral Hospital Kenyatta Teaching University, Nairobi, Kenya.
  • Garissa Cancer Center, Garissa County Hospital, Garissa, Kenya.
  • Department of Oncology, Antwerp University Hospital, Edegem, Belgium.

ORCID-Profile: Khalid El Bairi, Salma Najem, Arman Reza Chowdhury, Abeid Omar, Omar Abdihamid, Laure-Anne Teuwen, Nada Benhima, Ainhoa Madariaga, Fernando Cristobal Diaz, Kristina Jenei, Nazik Hammad, Miriam Mutebi, Dario Trapani

Förderung

  • NCI NIH HHS

Zitieren

APA

El Bairi, K., Najem, S., Chowdhury, A. R., Omar, A., Abdihamid, O., Teuwen, L. A., Benhima, N., Madariaga, A., Elkefi, S., Diaz, F. C., Hussain, S., Jenei, K., Hammad, N., Mutebi, M., Rubagumya, F., Trapani, D., El Kadmiri, N., Laouali, N., & Fourtassi, M. (2024). Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study. JCO Global Oncology. https://doi.org/10.1200/go.24.00167

Vancouver

El Bairi K, Najem S, Chowdhury AR, Omar A, Abdihamid O, Teuwen LA, et al. Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study. JCO Global Oncology. 2024. doi:10.1200/go.24.00167

BibTeX
@article{ElBairi2024,
  author = {El Bairi, Khalid and Najem, Salma and Chowdhury, Arman Reza and Omar, Abeid and Abdihamid, Omar and Teuwen, Laure-Anne and Benhima, Nada and Madariaga, Ainhoa and Elkefi, Safa and Diaz, Fernando Cristobal and Hussain, Sadaqat and Jenei, Kristina and Hammad, Nazik and Mutebi, Miriam and Rubagumya, Fidel and Trapani, Dario and El Kadmiri, Nadia and Laouali, Nasser and Fourtassi, Maryam},
  title = {Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.24.00167}
}
Kostenlos starten →